Fortis Healthcare has notified the stock exchanges of an upcoming board meeting scheduled for Friday, May 22, 2026, in compliance with Regulation 29(1) and 50(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was issued by the Company Secretary and Compliance Officer, Satyendra Chauhan.

Agenda for the Board Meeting

The board meeting has been convened to address key financial and shareholder-related matters for the financial year ended March 31, 2026. The following items are on the agenda:

Trading Window Closure

In continuation of the company's earlier communication dated March 25, 2026, regarding the closure of the trading window, Fortis Healthcare has reiterated that the trading window for dealing in the company's securities will remain closed until 48 hours after the declaration of the audited results — that is, up to May 24, 2026. This measure is in accordance with applicable SEBI regulations governing insider trading restrictions during periods of material unpublished price-sensitive information.

Key Details at a Glance

The board meeting will cover both standalone and consolidated audited financials, providing a comprehensive view of Fortis Healthcare's performance for FY26. The consideration of a final dividend, if any, will be an additional point of interest for equity shareholders of the company.

Fortis Healthcare Limited has provided a material litigation update to stock exchanges regarding ongoing proceedings in the Tokyo District Court. The healthcare company disclosed developments in a case involving its promoter shareholder Northern TK Venture Pte Ltd (NTK) against Daiichi Sankyo Company Limited.

Court Proceedings Concluded

The Tokyo District Court has completed both preparatory and oral proceedings in the litigation case filed by Northern TK Venture against Daiichi Sankyo Company Limited. The court proceedings reached this milestone on April 28, 2026, marking a significant development in the ongoing legal matter.

Regulatory Compliance and Disclosure

Fortis Healthcare made this disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. The announcement references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, demonstrating compliance with regulatory requirements for material event disclosures.

This represents the latest in a series of updates the company has provided to exchanges, with previous announcements dating from November 14, 2023 through February 19, 2026. The systematic disclosure pattern reflects the company's commitment to keeping stakeholders informed about material developments.

IHH Healthcare Connection

The disclosure includes an announcement from IHH Healthcare Berhad, made on April 28, 2026, on both the Malaysian Stock Exchange (Bursa Malaysia) and SGX Stock Exchange. IHH Healthcare's involvement stems from the complex corporate structure involving Northern TK Venture as an indirect wholly-owned subsidiary.

The litigation relates to previous transactions including:

• Subscription of 235,294,117 new equity shares in Fortis Healthcare
• Mandatory open offer for acquisition of up to 197,025,660 Fortis shares
• Related open offer for Malar Hospitals Limited shares

Next Steps and Timeline

With court proceedings now concluded, attention turns to the scheduled judgment announcement on September 10, 2026. Fortis Healthcare has committed to providing further updates in case of any material developments regarding this matter.

The company maintains its disclosure obligations under SEBI regulations, ensuring stakeholders receive timely information about significant legal proceedings that may impact the organization. The structured approach to these announcements demonstrates adherence to corporate governance standards and regulatory compliance requirements.